Literature DB >> 29916101

RUNX3 inhibits glioma survival and invasion via suppression of the β-catenin/TCF-4 signaling pathway.

Jikui Sun1,2,3,4, Banban Li5, Zhifan Jia3,4,6,7, Anling Zhang3,4,6,7, Guangxiu Wang3,4,6,7, Zhijuan Chen3,4,6,7, Zhende Shang1,2, Chaocai Zhang8, Jian Cui9, Weidong Yang10,11,12,13.   

Abstract

INTRODUCTION: Runt-related transcription factor 3 (RUNX3) exerts a tumor suppressor gene associated with gastric and other cancers, including glioma. However, how its anti-tumor mechanism in functions glioma is unclear.
METHODS: We assayed expression of RUNX3 with a tissue microarray (TMA), frozen cancer tissues and malignant glioma cell lines using immunohistochemistry, qRT-PCR and Western bolt analysis. Cell proliferation, invasion, cell cycle distribution and apoptosis were also examined to confirm the effect of RUNX3 medicated malignant phenotype. TOP/FOP experiment was used to detect the β-catenin/Tcf-4 transcription activity by RUNX3.
RESULTS: Enforced RUNX3 expression inhibited proliferation and invasion, induced cell cycle arrest and promoted apoptosis in vitro and in vivo, Bim siRNA partically reversed the effect of RUNX3-induced apoptosis in LN229 and U87 cells, suggesting a dependent role of Bim-caspase pathway. Moreover, Mechanism investigations revealed that restoration of RUNX3 suppressed β-catenin/Tcf-4 transcription activity.
CONCLUSIONS: RUNX3 plays a pivotal role in glioma initiation and progression as a tumor suppressor via attenuation of Wnt signaling, highlighting it as a potential therapeutic target for glioma.

Entities:  

Keywords:  Glioma; RUNX3; TCF-4; β-Catenin

Mesh:

Substances:

Year:  2018        PMID: 29916101     DOI: 10.1007/s11060-018-2927-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

Review 1.  Wnt/beta-catenin signaling in glioma.

Authors:  Kailiang Zhang; Junxia Zhang; Lei Han; Peiyu Pu; Chunsheng Kang
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-28       Impact factor: 4.147

2.  Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status.

Authors:  Xuan Zhou; Yu Ren; Lynette Moore; Mei Mei; Yongping You; Peng Xu; Baoli Wang; Guangxiu Wang; Zhifan Jia; Peiyu Pu; Wei Zhang; Chunsheng Kang
Journal:  Lab Invest       Date:  2010-01-04       Impact factor: 5.662

3.  Identification of RUNX3 as a component of the MST/Hpo signaling pathway.

Authors:  Boram Min; Min-Kyu Kim; Joo-Won Zhang; Jiyeon Kim; Kwang-Chul Chung; Byung-Chul Oh; Gary S Stein; Yong-Hee Lee; Andre J van Wijnen; Suk-Chul Bae
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

4.  Runx3 suppresses gastric cancer metastasis through inactivation of MMP9 by upregulation of TIMP-1.

Authors:  Yu Chen; Xufeng Wei; Changcun Guo; Haifeng Jin; Zheyi Han; Ying Han; Taidong Qiao; Kaichun Wu; Daiming Fan
Journal:  Int J Cancer       Date:  2011-06-21       Impact factor: 7.396

5.  RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration.

Authors:  Peng-Jin Mei; Jin Bai; Hui Liu; Chen Li; Yong-Ping Wu; Zheng-Quan Yu; Jun-Nian Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-16       Impact factor: 4.553

Review 6.  Tumor suppressor activity of the TGF-beta pathway in human cancers.

Authors:  S D Markowitz; A B Roberts
Journal:  Cytokine Growth Factor Rev       Date:  1996-06       Impact factor: 7.638

7.  A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models.

Authors:  Tugba Bagci-Onder; Hiroaki Wakimoto; Maarten Anderegg; Cody Cameron; Khalid Shah
Journal:  Cancer Res       Date:  2010-11-17       Impact factor: 12.701

8.  Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis.

Authors:  A R Ramjaun; S Tomlinson; A Eddaoudi; J Downward
Journal:  Oncogene       Date:  2006-08-14       Impact factor: 9.867

9.  RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer.

Authors:  Zhihai Peng; Daoyan Wei; Liwei Wang; Huamei Tang; Jun Zhang; Xiangdong Le; Zhiliang Jia; Qiang Li; Keping Xie
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

10.  RUNX3 mediates suppression of tumor growth and metastasis of human CCRCC by regulating cyclin related proteins and TIMP-1.

Authors:  Lijie He; Xiaodi Zhao; Hanmin Wang; Peng Zhang; Changcun Guo; Chen Huang; Xiaowei Liu; Fangfang Yao; Yu Chen; Weijuan Lou; Shiren Sun; Daiming Fan
Journal:  PLoS One       Date:  2012-03-22       Impact factor: 3.240

View more
  10 in total

1.  Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma.

Authors:  Xiaohong Guo; Yuwen Wang; Liangyan Yang; Pengyun Wang; Kan Chen; Lei Zhou; Yue Wu
Journal:  Int Ophthalmol       Date:  2021-04-24       Impact factor: 2.031

2.  RUNX3 is up-regulated in abdominal aortic aneurysm and regulates the function of vascular smooth muscle cells by regulating TGF-β1.

Authors:  Zhongxiao Zhou; Haimeng Zhou; Xin Zou; Xiaowei Wang
Journal:  J Mol Histol       Date:  2021-11-23       Impact factor: 3.156

3.  miR-301a promotes lung tumorigenesis by suppressing Runx3.

Authors:  Xun Li; Mingtian Zhong; Jiexuan Wang; Lei Wang; Zhanwen Lin; Zhi Cao; Zhujuan Huang; Fengxue Zhang; Yong Li; Ming Liu; Xiaodong Ma
Journal:  Mol Cancer       Date:  2019-05-23       Impact factor: 27.401

4.  miR-148-3p Inhibits Growth of Glioblastoma Targeting DNA Methyltransferase-1 (DNMT1).

Authors:  Yongtao Li; Fanyu Chen; Jiancheng Chu; Chao Wu; Yuan Li; Heng Li; Hongxin Ma
Journal:  Oncol Res       Date:  2019-04-08       Impact factor: 5.574

5.  Melanotic Neuroectodermal Tumor of Infancy (MNTI) and Pineal Anlage Tumor (PAT) Harbor A Medulloblastoma Signature by DNA Methylation Profiling.

Authors:  Oscar Lopez-Nunez; Rita Alaggio; Ivy John; Andrea Ciolfi; Lucia Pedace; Angela Mastronuzzi; Francesca Gianno; Felice Giangaspero; Sabrina Rossi; Vittoria Donofrio; Giuseppe Cinalli; Lea F Surrey; Marco Tartaglia; Franco Locatelli; Evelina Miele
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

Review 6.  Wnt/β-catenin signaling in cancers and targeted therapies.

Authors:  Fanyuan Yu; Changhao Yu; Feifei Li; Yanqin Zuo; Yitian Wang; Lin Yao; Chenzhou Wu; Chenglin Wang; Ling Ye
Journal:  Signal Transduct Target Ther       Date:  2021-08-30

7.  RUNX3/H3K27me3 Co-Expression Defines a Better Prognosis in Surgically Resected Stage I and Postoperative Chemotherapy-Naive Non-Small-Cell Lung Cancer.

Authors:  Xiaohui Chen; Yujie Deng; Chuanzhong Huang; Yi Shi; Jianping Lu; Guibin Weng; Weifeng Zhu; Kunshou Zhu; Junqiang Chen; Jiancheng Li
Journal:  J Oncol       Date:  2022-03-24       Impact factor: 4.375

Review 8.  Complex Interplay between the RUNX Transcription Factors and Wnt/β-Catenin Pathway in Cancer: A Tango in the Night.

Authors:  Kerri Sweeney; Ewan R Cameron; Karen Blyth
Journal:  Mol Cells       Date:  2020-02-29       Impact factor: 5.034

9.  RUNX3 Inhibits the Invasion and Metastasis of Human Colon Cancer HT-29 Cells by Upregulating MMP-2/9.

Authors:  Jun Xue; Xueliang Wu; Ming Qu; Fei Guo; Lei Han; Guangyuan Sun; Zelong Yuan; Shuang Fan; Tian Li
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-27       Impact factor: 2.629

10.  RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/β-catenin signaling pathway.

Authors:  Jikui Sun; Quanfeng Ma; Banban Li; Chen Wang; Lidong Mo; Xuebin Zhang; Fan Tang; Qiong Wang; Xiaoling Yan; Xiuhua Yao; Qiaoli Wu; Chang Shu; Jinbiao Xiong; Weijia Fan; Jinhuan Wang
Journal:  Cell Death Dis       Date:  2020-10-22       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.